Scarica l'app Stockscreener
1.64
0.61%
0.01
Dopo l'orario di chiusura:
1.63
-0.01
-0.61%
Precedente Chiudi:
$1.63
Aprire:
$1.63
Volume 24 ore:
6.86M
Relative Volume:
1.23
Capitalizzazione di mercato:
$197.03M
Reddito:
-
Utile/perdita netta:
$-225.14M
Rapporto P/E:
-0.8367
EPS:
-1.96
Flusso di cassa netto:
$-192.27M
1 W Prestazione:
+34.43%
1M Prestazione:
+41.38%
6M Prestazione:
+230.11%
1 anno Prestazione:
+80.92%
Intervallo 1D:
$1.60
$1.785
Intervallo di 1 settimana:
$1.145
$1.785
Portata 52W:
$0.3546
$2.74
Invivyd Inc Stock (IVVD) Company Profile
Nome
Invivyd Inc
Settore
Industria
Telefono
(781) 819-0080
Indirizzo
1601 TRAPELO ROAD, WALTHAM
Confronta IVVD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.64 | 349.49M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-04-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-03-26 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | Iniziato | H.C. Wainwright | Buy |
Invivyd Inc Borsa (IVVD) Ultime notizie
Are Investors Undervaluing Invivyd, Inc. (NASDAQ:IVVD) By 31%? - 富途牛牛
Invivyd (IVVD) Is Up 26.8% After FDA Clears Phase 3 Trials for COVID Antibody Candidate - simplywall.st
Invivyd (IVVD): Assessing Valuation After FDA Clears Phase 3 COVID-19 Antibody Trial - Yahoo Finance
D. Boral Capital Maintains Invivyd (IVVD) Buy Recommendation - Nasdaq
Invivyd receives FDA clearance for COVID antibody prevention trials By Investing.com - Investing.com Nigeria
D. Boral Capital Increases Invivyd (NASDAQ:IVVD) Price Target to $2.00 - MarketBeat
Invivyd, Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application and Provide Feedback to Advance the Company's Revolation Clinical Program - MarketScreener
New Haven biotech advances vaccine-alternative to prevent COVID - Hartford Business Journal
Invivyd stock soars after FDA clears IND for COVID antibody candidate - Investing.com
Cantor Fitzgerald Initiates Invivyd at Overweight With $10 Price Target - MarketScreener
This Commerce Bancshares Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Invivyd Shares Climb After FDA Advances Its Covid-Preventing Drug - MarketScreener
Invivyd, Inc. (NASDAQ:IVVD) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Invivyd (NASDAQ:IVVD) Now Covered by Cantor Fitzgerald - MarketBeat
Invivyd announces IND clearance, alignment with FDA on VYD2311 program - TipRanks
Invivyd’s VYD2311 Receives FDA Clearance for Trials - TipRanks
Invivyd receives FDA clearance for COVID antibody prevention trials - Investing.com
Invivyd gets FDA nod to start key trial of COVID-blocking antibody VYD2311 - MarketScreener
Invivyd Announces Upcoming Phase 3 Clinical Trials for VYD2311, a Novel COVID Prevention Therapy - Quiver Quantitative
Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID - Yahoo Finance
How supply chain issues affect Invivyd Inc. stockWeekly Gains Summary & High Conviction Trade Alerts - newser.com
Is Invivyd Inc. stock in correction or buying zone2025 AllTime Highs & Daily Volume Surge Trade Alerts - newser.com
What to do if you’re stuck in Invivyd Inc.Exit Point & Fast Exit and Entry Trade Guides - newser.com
Earnings visualization tools for Invivyd Inc.July 2025 Intraday Action & Daily Profit Focused Screening - newser.com
How Invivyd Inc. stock performs in interest rate cyclesGap Down & Weekly Return Optimization Plans - newser.com
Why retail investors pile into Invivyd Inc. stockJuly 2025 Outlook & Precise Trade Entry Recommendations - newser.com
How moving averages guide Invivyd Inc. tradingPortfolio Performance Summary & Fast Moving Stock Trade Plans - newser.com
Multi asset correlation models including Invivyd Inc.July 2025 Action & Free Growth Oriented Trading Recommendations - newser.com
Is Invivyd Inc. stock safe for conservative investorsWeekly Investment Report & Fast Momentum Entry Tips - newser.com
Applying chart zones and confluence areas to Invivyd Inc.2025 Investor Takeaways & Long-Term Safe Investment Plans - newser.com
Can you recover from losses in Invivyd Inc.2025 Winners & Losers & Growth Focused Stock Pick Reports - newser.com
Is Invivyd Inc a good long term investmentVolume Analysis Techniques & Free Double Digit Growth Tips - earlytimes.in
What analysts say about Invivyd Inc stockStock Rotation Strategies & Small Budget Trading Ideas - earlytimes.in
Invivyd Appoints New Director Amid Nasdaq Compliance - The Globe and Mail
Invivyd appoints Wave Life Sciences CEO to board of directors By Investing.com - Investing.com Australia
Invivyd appoints Wave Life Sciences CEO to board of directors - Investing.com
Invivyd Appoints Paul B. Bolno, M.D. To Its Board Of Directors - TradingView
Invivyd, Inc. Appoints Dr. Paul B. Bolno to Board of Directors - Quiver Quantitative
Invivyd appoints Wave Life Sciences CEO Paul Bolno to board - TipRanks
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors - The Manila Times
How to contact the Daily Bulletin - FinancialContent
Invivyd Inc Azioni (IVVD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.05%
4.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):